PA
TRIN icon

PharVision Advisers’s Trinity Capital TRIN Stock Holding History

PharVision Advisers’s Portfolio TRIN Stock Details TRIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,488
Closed -$373K – 797
2025
Q2 		$373K Buy
26,488
+12,527
+90% +$181K 0.54% 35
2025
Q1 		$212K Buy
+13,961
New +$217K 0.29% 186

Other funds holding TRIN

UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
MW
Melia Wealth Tulsa, Oklahoma $207M AUM 13.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PharVision Advisers's TRIN Position: Q3 2025 in Review

PharVision Advisers sold out of Trinity Capital (TRIN) in Q3 2025, closing a stake of 26,488 shares — an estimated $373K sold.

PharVision Advisers first reported a position in TRIN in Q1 2025 and held it in 2 quarters. The position peaked at $373K in Q2 2025. 133 funds tracked by Wall St. Rank hold TRIN as of Q3 2025.

  • PharVision Advisers reported no remaining Trinity Capital position as of Q3 2025 after selling out during the quarter.
  • PharVision Advisers sold 26,488 Trinity Capital shares in Q3 2025, an estimated $373K.
  • PharVision Advisers first reported a position in Trinity Capital in Q1 2025 and held it in 2 quarters.
  • PharVision Advisers's Trinity Capital position peaked at $373K in Q2 2025.
  • 133 funds tracked by Wall St. Rank held Trinity Capital as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.